Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study.
Barzilay JI, Gao P, Rydén L, Schumacher H, Probstfield J, Commerford P, Dans A, Ferreira R, Keltai M, Paolasso E, Yusuf S, Teo K; TRANSCEND Investigators. Barzilay JI, et al. Among authors: probstfield j. Diabetes Care. 2011 Sep;34(9):1902-7. doi: 10.2337/dc11-0545. Epub 2011 Jul 25. Diabetes Care. 2011. PMID: 21788624 Free PMC article. Clinical Trial.
Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.
Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, Probstfield J, Dagenais GR, Teo K, Yusuf S; ONTARGET and TRANSCEND Investigators. Barzilay JI, et al. Among authors: probstfield j. Arch Intern Med. 2011 Jan 24;171(2):142-50. doi: 10.1001/archinternmed.2010.502. Arch Intern Med. 2011. PMID: 21263104
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators. Verdecchia P, et al. Among authors: probstfield j. Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21. Circulation. 2009. PMID: 19770395 Clinical Trial.
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Böhm M, et al. Among authors: probstfield j. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15. Circulation. 2010. PMID: 20231536 Clinical Trial.
Effect of telmisartan on renal outcomes: a randomized trial.
Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Mann JF, et al. Among authors: probstfield jl. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. doi: 10.7326/0003-4819-151-1-200907070-00122. Epub 2009 May 18. Ann Intern Med. 2009. PMID: 19451556 Free article. Clinical Trial.
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators. Dehghan M, et al. Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234. Circulation. 2012. PMID: 23212996 Clinical Trial.
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Chang Yu P, Ryden LE, Pirags V, Spinas GA, Birkeland KI, Ratner RE, Marin-Neto JA, Keltai M, Riddle MC, Bosch J, Yusuf S, Gerstein HC; ORIGIN Trial Investigators. Bordeleau L, et al. Among authors: probstfield j. Diabetes Care. 2014;37(5):1360-6. doi: 10.2337/dc13-1468. Epub 2014 Feb 26. Diabetes Care. 2014. PMID: 24574355 Clinical Trial.
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Böhm M, Baumhäkel M, Probstfield JL, Schmieder R, Yusuf S, Zhao F, Koon T; ONTARGET/TRANSCEND ED-Investigators. Böhm M, et al. Am Heart J. 2007 Jul;154(1):94-101. doi: 10.1016/j.ahj.2007.03.024. Am Heart J. 2007. PMID: 17584560 Clinical Trial.
255 results